scholarly journals Clinical Experience with Image-guided Robotic Radiosurgery (the Cyberknife) in the Treatment of Brain and Spinal Cord Tumors

1998 ◽  
Vol 38 (11) ◽  
pp. 780-783 ◽  
Author(s):  
Steven D. CHANG ◽  
Martin MURPHY ◽  
Paul GEIS ◽  
David P. MARTIN ◽  
Steven L. HANCOCK ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Clinical Experience ◽  
Spinal Cord Tumors ◽  
Image Guided ◽  
Robotic Radiosurgery ◽  
Brain And Spinal Cord

scholarly journals Objective assessment of utility of intraoperative ultrasound in resection of central nervous system tumors: A cost-eff ective tool for intraoperative navigation in neurosurgery

2011 ◽  
Vol 02 (01) ◽  
pp. 004-011 ◽  
Author(s):  
Aliasgar Moiyadi ◽  
Prakash Shetty
Keyword(s):  
Spinal Cord ◽  
Objective Assessment ◽  
Tumor Resection ◽  
Intraoperative Ultrasound ◽  
Frameless Stereotaxy ◽  
Spinal Cord Tumors ◽  
Individual Parameter ◽  
Objective Evidence ◽  
Intraoperative Localization ◽  
Brain And Spinal Cord

ABSTRACT Background: Localization and delineation of extent of lesions is critical for safe maximal resection of brain and spinal cord tumors. Frame-based and frameless stereotaxy and intraoperative MRI are costly and not freely available especially in economically constrained nations. Intraoperative ultrasound has been around for a while but has been relegated to the background. Lack of objective evidence for its usefulness and the perceived “user unfriendliness” of US are probably responsible for this. We recount our experience with this “forgotten” tool and propose an objective assessment score of its utility in an attempt to revive this practice. Materials and Methods: Seventy seven intraoperative ultrasound (IOUS) studies were carried out in patients with brain and spinal cord tumors. Seven parameters were identifi ed to measure the “utility” of the IOUS and a “utility score” was devised (minimum 0 and maximum 7). Individual parameter and overall scores were calculated for each case. Results: IOUS was found to be useful in many ways. The median overall score was 6 (mean score 5.65). There were no scores less than 4 with the majority demonstrating usefulness in 5 or more parameters (91%). The use of the IOUS signifi cantly infl uenced the performance of the surgery in these cases without signifi cantly prolonging surgery. Conclusions: The IOUS is a very useful tool in intraoperative localization and delineation of lesions and planning various stages of tumor resection. It is easy, convenient, reliable, widely available, and above all a cost-eff ective tool. It should be increasingly used by neurosurgeons in the developing world where costlier intraoperative localization and imaging is not available freely.

Imprints, Smears, and Frozen Sections of Brain Tumors

Neurosurgery ◽  
1991 ◽  
Vol 29 (4) ◽  
pp. 575-579 ◽  
Author(s):  
Marc G. Reyes ◽  
Fayez M. Homsi ◽  
Larry W. McDonald ◽  
Roberta P. Glick
Keyword(s):  
Spinal Cord ◽  
Middle Fossa ◽  
Frozen Sections ◽  
Spinal Cord Tumors ◽  
Paraffin Sections ◽  
Intraoperative Diagnosis ◽  
The Central Nervous System ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Brain And Spinal Cord

Abstract In this study, we compared the suitability and accuracy of imprints, smears, and frozen sections of suspected brain and spinal cord tumors of 150 patients. Eighty-six percent of the imprints, 91% of the smears, and 99% of the frozen sections were suitable for interpretation. Among the suitable preparations, 82% of the imprints, 92% of the smears, and 99% of the frozen sections agreed with our diagnosis on paraffin sections. Although frozen sections were clearly more accurate than imprints and smears, the latter two provided diagnoses in patients with acquired immunodeficiency syndrome where frozen sections were not done to avoid contaminating our cryostat and in a patient with an epidermoid cyst of the middle fossa that could not be adequately frozen sectioned. Our study shows that imprints and smears complement frozen sections in the intraoperative diagnosis of tumors of the central nervous system.

Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 2563-2563
Author(s):  
Sylvia Christine Kurz ◽  
Rohinton Tarapore ◽  
Yazmin Odia ◽  
Nicholas A. Butowski ◽  
Carl Johannes Koschmann ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Spinal Cord ◽  
Clinical Experience ◽  
Pediatric Patients ◽  
Single Agent ◽  
Combination Group ◽  
Survival Times ◽  
Spinal Cord Tumors ◽  
Two Phase ◽  
Agent Group

2563 Background: High-grade gliomas of the spinal cord are a rare and understudied entity, representing < 5% of all spinal cord tumors. Reported median survival times range from 10-16 months. Up to 53% of tumors harbor the H3 K27M mutation, which is associated with an unfavorable prognosis. Postsurgical treatment often includes radiation ± temozolomide, although the role of chemotherapy has not been conclusively established. At recurrence, there are no effective therapies and most clinical studies exclude patients with spinal cord tumors. We report our clinical experience with ONC201, a small molecule DRD2 antagonist and caseinolytic protease P agonist, in patients with recurrent H3 K27M-mutant diffuse gliomas of the spinal cord (scDG). Methods: Adults and children with recurrent H3 K27M-mutant scDG received ONC201 in two Phase II clinical trials enrolling adult recurrent H3 K27M-mutant glioma patients (NCT02525692; NCT03295396) and in one Phase I clinical trial enrolling pediatric patients (NCT03416530). Adult patients received ONC201 at the RP2D dose of 625 mg weekly and pediatric patients received the RP2D of 625 mg weekly, scaled by body weight. All patients began ONC201 as a single agent until disease progression. Five patients continued ONC201 combined with bevacizumab beyond progression. Results: As of January 15, 2020, 12 evaluable patients (adult n = 8, pediatric n = 4) received ONC201. The median age was 20.9 (range: 7-72) years. The median follow-up time for the single agent ONC201 group was 5.4 (range 1.3-9.7) months while that of the combination group is 7.4 (range 6.2-25.1) months. The median number of ONC201 doses was 10 (range: 5-39) for the ONC201 single agent group and 34 (range: 21-100) for the combination group. Five of 7 patients remain alive in the ONC201 single agent group while 3 of 5 patients remain alive in the combination group. Three patients in the ONC201 single agent group and 2 patients in the combination group continue on treatment. There were no drug-related toxicities requiring dose reduction or discontinuation. Conclusions: Treatment with ONC201 alone or combined with bevacizumab is well tolerated in patients with recurrent H3 K27M-mutant scDG and a subset of patients experiences prolonged survival that exceeds historical outcomes. Clinical trial information: NCT02525692; NCT03295396; NCT03416530 .

scholarly journals Epidemiology of Primary Brain and Spinal Cord Tumors in Iran: a systematic review

2013 ◽  
Vol 1 (2) ◽  
pp. 13-20
Author(s):  
Seyed Behzad Jazayeri ◽  
Farhad Shokraneh ◽  
Rashid Ramezani ◽  
Marjan Alimi ◽  
Soheil Saadat ◽  
...  
Keyword(s):  
Systematic Review ◽  
Spinal Cord ◽  
Spinal Cord Tumors ◽  
Brain And Spinal Cord

Clinical Experience with Image-guided Robotic Radiosurgery (the Cyberknife) in the Treatment of Malignant Brain Tumors

Neurosurgery ◽  
1998 ◽  
Vol 43 (3) ◽  
pp. 692-693
Author(s):  
D. Chang Steven ◽  
P. Martin David ◽  
Geis Paul ◽  
L. Hancock Steven ◽  
R. Adler John
Keyword(s):  
Brain Tumors ◽  
Clinical Experience ◽  
Image Guided ◽  
Malignant Brain Tumors ◽  
Robotic Radiosurgery

Secondary brain and spinal cord tumors

2014 ◽  
pp. 457-464
Author(s):  
Rimas V. Lukas ◽  
Patrik Gabikian ◽  
Steven J. Chmura
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Tumors ◽  
Brain And Spinal Cord
Sign in / Sign up

Export Citation Format

Share Document